Every new device gets a business case first
A laser platform is priced like a car and earns like a hotel room: only when it is booked. Before anything is signed, we build the model from the clinic's own numbers, treatments per week at the real price list, consumables and handpiece servicing per treatment, the payment on the financing quote, and the room hours honestly available once existing bookings are counted. The output is a break-even stated in treatments per week, tested at conservative utilization. A machine that only works with a full book is a finding, not a failure; sometimes the answer is to rent access, share a platform between rooms, or wait two quarters.
Demand for a new treatment ramps; the loan payment does not. The model carries a ramp curve rather than a cliff, first months light while the clinic markets the service and trains on it, so the cash plan funds the gap on purpose instead of meeting it as a surprise.
The same model settles the pricing argument. Once the capital cost per treatment is explicit, discounting a device service to fill the calendar stops being a feel decision and becomes arithmetic the whole team can see.
Loan or lease, decided on paper
Device vendors sell financing alongside hardware, and the offer in the sales quote deserves a competitor. Walla spent years on the banking side before founding Tauro, so the clinic's package goes to lenders the way lenders want to read it, and through Business Financing Advisory we put a bank or leasing alternative beside the vendor's paper before anyone signs.
| Equipment loan | Lease | |
|---|---|---|
| Who owns the machine | The clinic, from day one | The lessor, until any buyout |
| The deduction | Depreciation plus interest | Lease payments as paid |
| HST | Credit claimed on the full price up front | Credits claimed payment by payment |
| End of term | Keep it, trade it or sell it | Return, renew or buy out at the residual |
| Where it bites | Down payment and covenants | Effective rate hidden in the payment |
Neither column wins in general. A clinic with strong cash and a long-life platform usually buys; a clinic testing a new treatment category, where the technology may be superseded in three years, often leases the risk away. The point is to choose from a comparison, not from whichever rep was in the room.
Three margin engines, read separately
Injectables carry a per-unit product cost that moves with supplier pricing and loyalty-program rebates. Device treatments carry almost no marginal cost but must recover their capital, so their margin is a function of utilization. Retail skincare adds margin dollars at low effort but ties cash up on the shelf and expires there. One blended gross margin hides all three stories, which is why our monthly pack reports margin by service line plus revenue per treatment-room hour, the single number that says whether the binding constraint is rooms, injector hours or demand, and therefore whether the next dollar goes to a hire, a machine or marketing.
Commission plans sit inside the same lens. A percentage paid on a discounted device treatment can quietly hand the whole margin to the provider, so we test the commission grid against the service-line numbers once a year and after every price change.
Cash that is already spoken for
Package and membership money arrives ahead of the work, so the bank balance runs structurally ahead of the truth. We keep a 13-week cash-flow forecast beside a redemption schedule, so the portion of the account that belongs to future treatments stays visible when spending decisions get made. The rhythm is monthly: close the books, review the KPI pack, reforecast the quarter, and revisit the capital plan, with the second-location model built only when the first location's unit numbers have earned it.
This is what Fractional CFO means at Tauro for clinics across the GTA: senior finance judgment on a clinic's schedule and budget, sitting on books kept clean through End-to-End Accounting. Scope is quoted in writing after a free 15-minute discovery call, with no hourly surprises.
